C3L-03642
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 64.02190281
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.310
- XENOBIOTIC_METABOLISM+0.310
- KRAS_SIGNALING_DN+0.300
- COAGULATION+0.280
- PANCREAS_BETA_CELLS+0.260
- KRAS_SIGNALING_UP+0.230
- SPERMATOGENESIS+0.180
- ANGIOGENESIS+0.160
- ESTROGEN_RESPONSE_LATE+0.160
- ESTROGEN_RESPONSE_EARLY+0.130
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- E2F_TARGETS-0.530
- MYC_TARGETS_V1-0.520
- G2M_CHECKPOINT-0.470
- DNA_REPAIR-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.440
- OXIDATIVE_PHOSPHORYLATION-0.410
- INTERFERON_ALPHA_RESPONSE-0.400
- MTORC1_SIGNALING-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-H4-A2HO-01A-11R-A180-07 | — | — | 0.898 |
| 2 | TCGA-62-8397-01A-11R-2326-07 | — | cohortA1 | 0.886 |
| 3 | TCGA-G2-A2EK-01A-22R-A18C-07 | — | — | 0.876 |
| 4 | C3N-03911 | — | cohortA1 | 0.875 |
| 5 | TCGA-67-4679-01B-01R-1755-07 | — | cohortA1 | 0.865 |
| 6 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.864 |
| 7 | BS_912NX4Y0 | Ganglioglioma | — | 0.862 |
| 8 | BS_AKRHBPNZ | Ganglioglioma | — | 0.859 |
| 9 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.858 |
| 10 | TCGA-62-A46S-01A-11R-A24H-07 | — | cohortA3 | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |